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Summary
Background Previous estimates of the burden of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among 
people who inject drugs have not included estimates of the burden attributable to the consequences of past injecting. 
We aimed to provide these estimates as part of the Global Burden of Disease (GBD) Study 2013.
Methods We modelled the burden of HBV and HCV (including cirrhosis and liver cancer burden) and HIV at the 
country, regional, and global level. We extracted United Nations data on the proportion of notiﬁ ed HIV cases by 
transmission route, and estimated the contribution of injecting drug use (IDU) to HBV and HCV disease burden by 
use of a cohort method that recalibrated individuals’ history of IDU, and accumulated risk of HBV and HCV due to 
IDU. We estimated data on current IDU from a meta-analysis of HBV and HCV incidence among injecting drug 
users and country-level data on the incidence of HBV and HCV between 1990 and 2013. We calculated estimates of 
burden of disease through years of life lost (YLL), years of life lived with disability (YLD), deaths, and disability-
adjusted life-years (DALYs), with 95% uncertainty intervals (UIs) calculated for each metric.
Findings In 2013, an estimated 10·08 million DALYs were attributable to previous exposure to HIV, HBV, and HCV 
via IDU, a four-times increase since 1990. In total in 2013, IDU was estimated to cause 4·0% (2·82 million DALYs, 
95% UI 2·4 million to 3·8 million) of DALYs due to HIV, 1·1% (216 000, 101 000–338 000) of DALYs due to HBV, and 
39·1% (7·05 million, 5·88 million to 8·15 million) of DALYs due to HCV. IDU-attributable HIV burden was highest 
in low-to-middle-income countries, and IDU-attributable HCV burden was highest in high-income countries.
Interpretation IDU is a major contributor to the global burden of disease. Eﬀ ective interventions to prevent and treat 
these important causes of health burden need to be scaled up.
Funding Bill & Melinda Gates Foundation and Australian National Health and Medical Research Council.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
The consequences of HIV infection and chronic viral 
hepatitis—mainly hepatitis B and C—are among the 
top ten causes of death worldwide.1 Injecting drug 
use (IDU) is an important risk factor for all three 
infections because of sharing of contaminated injecting 
equipment. The prevalence of HIV among people who 
inject drugs varies substantially both among and within 
countries,2 and tends to be lower where comprehensive 
harm reduction and prevention strategies have been 
implemented.3 In many settings worldwide, more than 
half of people who inject drugs are infected with 
hepatitis C virus (HCV).4 Chronic infection occurs in 
75% of HCV infections,5 and 3–11% of chronic HCV 
carriers will develop liver cirrhosis within 20 years.6 
Generally, the burden of chronic hepatitis B virus (HBV) 
is higher among people who were infected as a child, 
and therefore, the proportion attributable to IDU is 
lower than that of HCV. A 2011 systematic review 
estimated that globally, 8% of people currently injecting 
were HBsAg positive.4
The prevalences of IDU and of HIV, HBV, and HCV 
infection among people who inject drugs2,4 have been 
systematically reviewed. We previously estimated the 
burden of these infections attributable to injection of 
drugs within the past year.7 However, no global estimates 
have been made of the burden attributable to historical 
IDU and exposure to these viruses. This is an important 
omission from estimates of burden due to chronic viral 
hepatitis because the health consequences of progression 
to chronic infection might not be seen for many decades 
after initial exposure.
In this Article, we summarise the results of the 
quantiﬁ cation of this cause of disease burden as part of 
the Global Burden of Disease Study (GBD) 2013.8,9 We 
summarise disease burden as years of life lost (YLL) due 
to premature mortality, years of life lived with disability 
(YLDs) in people living with the disorders, and disability-
adjusted life-years (DALYs). We estimated the global 
burden of disease (YLDs, YLLs, and DALYs) attributable 
to IDU as a risk factor for HIV, HBV, and HCV infection, 
and examine trends between 1990 and 2013; compare the 
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relative contribution of HIV, HBV, and HCV to total 
blood-borne virus burden attributed to IDU (YLDs, YLLs, 
and DALYs); and examine geographic variations in 
burden of disease attributable to IDU.
Methods
Overview
As part of GBD 2013, we measured the burden of hepatitis 
B and hepatitis C (including attributable cirrhosis and 
liver cancer) and HIV at the country, regional, and global 
level for each age–sex group for 1990–2013. These 
methods have been described in previous studies.1,8–11
Two of the key modelling approaches used in this 
exercise were Cause of Death Ensemble modelling 
(CODEm), an analytical tool that explores a variety of 
models to estimate trends in causes of death,12 and a 
disease epidemiology modelling approach that used 
an age-integrating Bayesian hierarchical model 
(DisMod-MR 2.0). These approaches have been 
described in full previously.1,8–10,12 For HIV, hepatitis B, 
and hepatitis C, we used disease-speciﬁ c natural 
history models to estimate deaths and YLDs, because 
the three-state model in DisMod-MR 2.0 (susceptible, 
cases, dead) did not capture the complexity of the 
disease processes.
Mortality estimation
We used CODEm12 to model mortality due to overall 
acute hepatitis based on vital registration data. Because 
of poor coverage of cause of death data for each of the 
varieties of acute hepatitis, we used four natural history 
models for hepatitis B and C to estimate mortality by 
deriving incidence from measurements of seroprevalence 
and multiplying this incidence by case fatality to estimate 
the number of deaths. These four models were then 
made to ﬁ t the parent cause-of-death model.
We estimated HIV mortality using a modiﬁ ed UNAIDS 
Spectrum model.9 This is a compartmental HIV 
progression model that generates age-speciﬁ c incidence, 
prevalence, and death rates by use of methods described 
in detail previously.9 This modelling approach was 
modiﬁ ed based on epidemic type. For concentrated 
epidemics (ie, in which HIV might be prevalent among 
some subpopulations, such as sex workers, people who 
inject drugs, or men who have sex with men, but has not 
spread widely to the general community), the Spectrum 
models were calibrated to align with vital registration 
data after correction for misclassiﬁ cation of deaths due to 
HIV. For generalised HIV epidemics (ie, in which HIV is 
established in the general population), we minimised a 
loss function to select the epidemic curves that were 
Research in context 
Evidence before this study
On Aug 4, 2016, we searched PubMed for “substance abuse, 
intravenous/epidemiology or substance-related disorders/
epidemiology” [MeSH] AND (burden OR DALY OR QALY OR HALE 
OR YLL OR YLD) AND (HIV OR HBV OR HCV OR “hepatitis C” OR 
“hepatitis B”), with no restrictions on language or date of 
publication, and found 206 publications. We excluded any 
studies that did not report original estimates of the frequency or 
burden of disease related to HIV, hepatitis B, or hepatitis C, that 
were not restricted to people who inject drugs, or that did not 
produce estimates for an area larger than a country. Only one 
article met our search criteria: an analysis of the burden of HIV, 
hepatitis B, and hepatitis C due to past-year injecting drug use, 
which was reported by our group from the Global Burden of 
Disease Study (GBD) 2010. The 2010 modelling approach meant 
that only health burden due to injecting in 2010 was captured. 
These estimates failed to capture any burden in 2010 due to 
exposure to these viruses via injecting that occurred before 2010. 
Consequently, hepatitis burden in 2010 due to injecting drug use 
exposure was seriously underestimated. No studies have 
reported original estimates of the total burden of HIV, hepatitis 
B, or hepatitis C in people who inject drugs, and no studies have 
reported global estimates of a comprehensive health gap metric 
(ie, disability-adjusted life-years or quality-adjusted life-years).
Added value of this study
We used data from GBD 2013 to estimate morbidity and 
mortality among people who inject drugs attributable to HIV, 
acute hepatitis B and C; and for cirrhosis and liver cancer due 
to hepatitis B virus (HBV), and hepatitis C virus (HCV) 
infection. We did so by sex, region, and country from 1990 to 
2013. Previous global reviews have reported the prevalence of 
HIV, hepatitis B surface antigen, and anti-HCV among active 
injecting drug users, but no study has examined the health 
burden in this population that results from historical exposure 
to these viruses via injecting and the later health eﬀ ects of 
chronic infection. This historical exposure is especially 
important for HCV, for which the health burden largely occurs 
decades after infection. To our knowledge, our study is the 
ﬁ rst attempt to estimate trends over time in the total burden 
of HIV, hepatitis B, and hepatitis C among people who inject 
drugs, using systematic data gathering and robust statistical 
methods. The burden of hepatitis C among people who inject 
drugs (jointly considering acute HCV infection, cirrhosis, and 
liver cancer) is much larger than that of HIV. 
Implications of all the available evidence
The health consequences of HIV and viral hepatitis 
attributable to injecting drug use are major causes of 
premature death and disability worldwide. Injecting drug use 
is the cause of a substantial proportion of global HCV burden. 
These data are crucial to underpin new global eﬀ orts to tackle 
viral hepatitis and HIV. 
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most consistent with the prevalence and all-cause 
mortality data.9
The major burden of mortality from viral hepatitis is 
caused by cirrhosis and liver cancer resulting from 
chronic hepatitis infection. We modelled cirrhosis 
mortality based mainly on vital registration data using 
CODEm. We used aetiological proportion models 
estimated with DisMod-MR 2.0 to split the parent 
cirrhosis estimates into cases of cirrhosis attributable to 
HBV, HCV, alcohol, and other causes.1,8–11
We modelled liver cancer mortality using cancer 
registry data. These data were transformed into mortality 
estimates with mortality-to-incidence ratios. The 
mortality estimates from cancer registries were then 
added to vital registration system data and the ﬁ nal 
mortality estimates for liver cancer were generated with 
CODEm. Aetiological proportions for liver cancer due to 
HBV, HCV, alcohol, and other causes were generated 
with DisMod-MR 2.0.
Estimation of YLDs
For non-fatal burden of disease, we estimated the 
incidence of HBV and HCV infection using sero-
prevalence data in DisMod-MR 2.0 (full details have 
already been reported previously).11,13 For hepatitis B, we 
used data on the seroprevalence of HBsAg (a marker of 
chronic infection), excess mortality, and remission to 
estimate incidence of HBV infection. For HCV, we used 
data on seroprevalence of HCV antibody (a marker of 
ever being infected), remission, and mortality to 
estimate HCV incidence. We also estimated incidence 
and prevalence of decompensated cirrhosis in 
DisMod-MR 2.0 using hospital data on cirrhosis (data 
available from 28 countries, using ICD codes that 
matched those used for processing cause of death data1) 
and cause-speciﬁ c mortality rate data. Full details of the 
modelling process and source data are presented in 
the Article on GBD 2013 hepatitis burden, including 
in the appendix.11
We derived incidence of liver cancer by dividing 
mortality by the mortality-to-incidence ratios. Mortality-
to-incidence ratios were then used to predict liver cancer 
survival. Finally, we estimated prevalence as a function of 
incidence and survival by splitting prevalence into four 
phases. Each phase had diﬀ erent disability weights, 
which were used to generate YLDs for that phase. Finally, 
we estimated incidence of HIV using the UNAIDS 
Spectrum modelling approach.9
Burden of HIV attributable to IDU
To estimate the burden of HIV cases attributable to IDU, 
we extracted data on the proportion of notiﬁ ed HIV 
See Online for appendix
1990 2013
Mean DALYs (95% UI) Age-standardised DALY 
rate per 100 000
Population 
attributable fraction 
Mean DALYs (95% UI) Age-standardised 
DALY rate per 100 000
Population 
attributable fraction
Andean Latin America <500 (<500 to <500) 0·6 1% 1000 (1000–3000) 2·6 1%
Australasia 1000 (1000–1000) 3·8 4% <500 (<500 to <500) 0·6 4%
Caribbean 5000 (2000–11 000) 15·8 1% 8000 (5000–12 000) 17·0 1%
Central Asia 5000 (1000–16 000) 7·7 59% 69 000 (40 000–104 000) 81·0 64%
Central Europe 2000 (1000–2000) 1·4 15% 7000 (5000–8000) 4·8 23%
Central Latin America <500 (<500 to <500) 0·2 <1% 1000 (1000–1000) 0·3 <1%
Central sub-Saharan Africa 19 000 (9000–33 000) 52·1 1% 42 000 (29 000–58 000) 60·5 1%
East Asia 1000 (<500–3000) 0·1 29% 171 000 (131 000–233 000) 10·1 26%
Eastern Europe 54 000 (31 000–82 000) 22·8 47% 551 000 (360 000–795 000) 228·3 44%
Eastern sub-Saharan Africa 53 000 (37 000–76 000) 41·2 1% 249 000 (198 000–305 000) 103·2 1%
High-income Asia Paciﬁ c <500 (<500 to <500) 0·0 1% <500 (<500 to <500) 0·1 1%
High-income North America 137 000 (102 000–175 000) 44·9 9% 49 000 (33 000–68 000) 12·8 10%
North Africa and Middle East 4000 (1000–15 000) 1·8 19% 91 000 (45 000–164 000) 18·0 23%
Oceania <500 (<500 to <500) 0·8 2% 3000 (1000–7000) 33·9 4%
South Asia 30 000 (9000–68 000) 3·2 1% 37 000 (22 000–58 000) 2·4 1%
Southeast Asia 24 000 (14 000–42 000) 5·9 17% 467 000 (217 000–1 529 000) 71·1 21%
Southern Latin America 3000 (2000–4000) 5·6 7% 6000 (4000–10 000) 9·7 6%
Southern sub-Saharan Africa 4000 (2000–7000) 9·3 1% 220 000 (139 000–312 000) 337·3 1%
Tropical Latin America 15 000 (10 000–22 000) 11·0 4% 22 000 (17 000–29 000) 10·2 5%
Western Europe 61 000 (44 000–84 000) 14·9 9% 26 000 (20 000–34 000) 5·2 10%
Western sub-Saharan Africa 58 000 (35 000–96 000) 41·2 5% 799 000 (633 000–1 000 000) 314·1 6%
Global 478 000 (402 000–565 000) 10·0 3% 2 818 000 (2 385 000–3 811 000) 38·6 4%
Burden is measured by as absolute numbers of DALYs, age-standardised DALY rates, and PAF. Estimates are rounded to the nearest thousand. Uncertainty intervals for DALY rates and PAFs are available in the 
appendix (pp 104–14). DALY=disability-adjusted life-year. 
Table 1: Burden of disease of HIV attributable to injecting drug use by region, 1990 and 2013 
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cases by transmission route from a number of agencies 
that conduct surveillance of HIV across the world.14–21 
This method of data collection produced 728 datapoints 
from 81 countries (appendix pp 3–51).
We estimated the proportion of HIV cases attributable 
to three transmission categories (sexual transmission, 
IDU, and other) for all country–time periods using 
DisMod-MR 2.0. The only covariate used in the model 
was one that added variance to the datapoints derived 
from data sources that attributed a portion of HIV cases 
to unknown transmission sources. We scaled the 
proportions from each of the three transmission models 
(sexual transmission, IDU, and other) to ensure that they 
summed to 100% of total HIV transmission by country, 
year, age, and sex.
Burden of HBV and HCV attributable to IDU
To estimate the relative contribution of IDU to the 
burden of HBV and HCV disease at the country, regional, 
and global level, we used a cohort method. We 
recalibrated individuals according to history of IDU and 
their accumulated risk of incident HBV and HCV due to 
IDU. We used data on current IDU, pooled in 
DisMod-MR 2.0; a meta-analysis of incidence rates of 
HBV and HCV among people who inject drugs (appendix 
pp 99, 100); and estimates of population-level incidence 
of HBV and HCV between 1990 and 2013. We used back 
extrapolation to estimate incidence before 1990.
To estimate the lifetime risk of being infected with 
HBV or HCV, we did a cohort analysis for each country, 
year, age, and sex category and estimated the probability 
of an individual having been infected in each preceding 
year. One of the main inputs to this cohort method was 
the probability of having injected drugs in a speciﬁ c age 
cohort in a given calendar year. For example, for a 
cohort of 40-year-olds in 2015, the relevant probability 
in 2005 is the estimated prevalence of IDU among 
30-year-olds.
In addition to a global time series of estimated 
prevalence of IDU, we also used the incidence of HBV or 
HCV and the seroconversion rate of HBV or HCV among 
people who inject drugs for each age–sex–country–year 
from 1960 to 2013, by 5-year age groups. Additional 
details are available in the appendix (pp 51–98).
We modelled the annual incidence rate of HBV and 
HCV using seroprevalence data in DisMod-MR 2.0. We 
assumed a low rate of remission (mean 0·015, 
SE 0·0075)22 in the HBV model to reﬂ ect the small 
proportion of patients whose infection clears 
spontaneously. We assumed zero remission for HCV.
1990 2013
Mean DALYs (95% CI) Age-standardised 
DALY rate per 100 000
Population 
attributable fraction 
(%)
Mean DALYs (95% CI) Age-standardised 
DALY rate per 100 000
Population 
attributable fraction 
(%)
Andean Latin America <500 (<500–1000) 1·6 1% 1000 (1000–2000) 3·0 2%
Australasia <500 (<500 to <500) 1·0 1% 1000 (<500–1000) 1·9 3%
Caribbean <500 (<500 to <500) 0·5 <1% <500 (<500–1000) 0·9 1%
Central Asia 1000 (1000–3000) 2·7 <1% 6000 (3000–10 000) 8·6 1%
Central Europe 3000 (1000–6000) 2·2 1% 7000 (3000–11 000) 4·5 3%
Central Latin America <500 (<500–1000) 0·4 1% 2000 (1000–3000) 1·0 1%
Central sub-Saharan Africa <500 (<500–1000) 1·1 <1% 1000 (<500–2000) 2·0 1%
East Asia 48 000 (18 000–89 000) 4·8 1% 96 000 (43 000–151 000) 5·6 1%
Eastern Europe 3000 (1000–5000) 1·2 1% 15 000 (6000–25 000) 5·8 4%
Eastern sub-Saharan Africa 1000 (<500–2000) 1·1 <1% 3000 (1000–5000) 1·6 1%
High-income Asia Paciﬁ c 4000 (2000–8000) 2·4 1% 8000 (4000–14 000) 3·2 2%
High-income North America 7000 (2000–13 000) 2·3 6% 20 000 (9000–34 000) 4·5 10%
North Africa and Middle East 2000 (1000–3000) 1·0 <1% 6000 (3000–10 000) 1·6 1%
Oceania <500 (<500 to <500) 5·0 1% 1000 (<500–1000) 9·4 1%
South Asia 2000 (1000–4000) 0·3 <1% 8000 (3000–12 000) 0·5 <1%
Southeast Asia 4000 (2000–8000) 1·3 <1% 16 000 (7000–26 000) 2·7 1%
Southern Latin America 1000 (1000–3000) 3·3 5% 3000 (1000–5000) 4·8 7%
Southern sub-Saharan Africa <500 (<500–1000) 0·8 <1% 1000 (<500–1000) 1·0 1%
Tropical Latin America 1000 (<500–2000) 0·8 1% 3000 (1000–5000) 1·4 2%
Western Europe 6000 (2000–10 000) 1·3 2% 12 000 (6000–20 000) 2·1 3%
Western sub-Saharan Africa 3000 (1000–5000) 2·3 <1% 7000 (3000–11 000) 3·3 1%
Global 88 000 (35 000–160 000) 2·1 1% 216 000 (101 000–338 000) 3·1 1%
Burden is measured as absolute numbers of DALYs, age-standardised DALY rates, and PAF. Estimates are rounded to the nearest thousand. Uncertainty intervals for DALY rates and PAFs are available in the 
appendix (pp 104–14). HBV=hepatitis B virus. DALY=disability-adjusted life-year.
Table 2: Burden of disease of HBV attributable to injecting drug use by region, 1990 and 2013 
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We generated pooled incidence rate for viral hepatitis 
from a meta-analysis of longitudinal epidemiological 
studies that reported an incidence rate for HBV23–27 or 
HCV23–38 among people who inject drugs (appendix 
pp 99,100). We calculated conﬁ dence intervals for the 
incidence rate (where no CI was reported) from a Poisson 
distribution around the number of cases. A meta-analysis 
was used to pool incidence rates as an input in our 
modelling strategy.
We excluded studies that focused on subgroups, such 
as people who had injected recently or adolescents 
because hepatitis incidence is far higher in those 
groups than for all people who inject drugs.39 We did 
not vary incidence among people actively injecting 
according to the availability of blood-borne virus 
prevention strategies (eg, needle and syringe 
programmes or opioid substitution therapy) because 
too few studies have examined incidence according to 
level of coverage and we were not able to estimate 
coverage by country over time. In any case, coverage in 
most countries remains very low among people who 
inject drugs,40 and would have been negligible in most 
countries until recent years.
We estimated the prevalence of current IDU using data 
and estimates from a review by the Reference Group to 
the UN on HIV and IDU.2 This review used a multistage 
process of systematic review that adhered to international 
guidelines. It involved multiple stages of peer and expert 
review, with searches of the peer-reviewed literature in 
addition to an extensive review of online grey literature 
databases related to drugs, alcohol, and HIV. We also 
collected additional data on the age and sex distribution 
of IDU for this modelling exercise (pp 101–03). We used 
DisMod-MR 2.0 to estimate the prevalence of IDU with 
year as a covariate to estimate the change in use over 
time. To project IDU prevalence from the baseline level 
in 1990 backwards in time to 1960, we took draws from a 
normal distribution of the coeﬃ  cient for the year 
covariate in the DisMod-MR 2.0 model. DisMod-MR 2.0 
makes an average estimate of the change in drug use 
over the time period from 1990 to 2013 and we used this 
coeﬃ  cient to extrapolate drug use back to 1960.
Analyses
For all of the inputs, we took 1000 draws to propagate 
uncertainty around our point estimates. Using each of 
these components, we calculated a mean population 
attributable fraction and 95% uncertainty interval (UI) 
from the 1000 draws for each GBD country, for each year 
(1990, 1995, 2000, 2005, 2010, and 2013) and 5-year age 
1990 2013
Mean DALYs (95% CI) Age-standardised 
DALY rate per 
100 000
Population 
attributable 
fraction (%)
Mean DALYs (95% CI) Age-standardised 
DALY rate per 
100 000
Population 
attributable 
fraction (%)
Andean Latin America 9000 (6000–14 000) 33·8 21% 49 000 (36 000–67 000) 103·0 39%
Australasia 6000 (4000–8000) 28·0 38% 21 000 (15 000–27 000) 59·4 59%
Caribbean 9000 (5000–13 000) 30·0 21% 32 000 (24 000–43 000) 73·2 38%
Central Asia 13 000 (7000–20 000) 24·2 10% 73 000 (53 000–100 000) 91·3 25%
Central Europe 86 000 (50 000–123 000) 65·5 30% 153 000 (119 000–193 000) 97·6 52%
Central Latin America 80 000 (48 000–118 000) 66·6 19% 241 000 (188 000–294 000) 109·7 31%
Central Sub-Saharan Africa 6000 (3000–9000) 16·5 9% 39 000 (23 000–56 000) 65·8 19%
East Asia 613 000 (428 000–803 000) 61·9 30% 2 425 000 (1 889 000–2 987 000) 140·5 49%
Eastern Europe 73 000 (41 000–110 000) 30·1 32% 605 000 (478 000–780 000) 231·1 68%
Eastern sub-Saharan Africa 45 000 (27 000–67 000) 39·3 18% 176 000 (131 000–225 000) 83·8 34%
High-income Asia Paciﬁ c 133 000 (74 000–208 000) 69·5 23% 373 000 (264 000–527 000) 144·5 46%
High-income North America 259 000 (169 000–346 000) 89·2 60% 810 000 (628 000–1 014 000) 177·2 81%
North Africa and Middle East 49 000 (29 000–74 000) 22·6 4% 119 000 (90 000–152 000) 29·6 7%
Oceania 2000 (1000–3000) 35·8 16% 7000 (4000–13 000) 85·5 28%
South Asia 49 000 (30 000–74 000) 5·5 3% 216 000 (140 000–316 000) 14·6 7%
Southeast Asia 104 000 (54 000–176 000) 30·5 14% 525 000 (357 000–719 000) 85·4 28%
Southern Latin America 47 000 (29 000–64 000) 109·0 56% 112 000 (90 000–135 000) 171·5 70%
Southern sub-Saharan Africa 8000 (4000–14 000) 21·0 19% 14 000 (8000–22 000) 23·2 26%
Tropical Latin America 104 000 (54 000–161 000) 80·1 35% 268 000 (195 000–361 000) 126·4 54%
Western Europe 376 000 (232 000–519 000) 88·3 44% 705 000 (570 000–838 000) 120·1 64%
Western sub-Saharan Africa 23 000 (14 000–37 000) 17·8 7% 84 000 (60 000–113 000) 37·4 11%
Global 2 095 000 (1 438 000–2 694 000) 48·6 23% 7 046 000 (5 882 000–8 153 000) 101·1 38%
Burden is measured as absolute numbers of DALYs, age-standardised DALY rates, and PAF. Estimates are rounded to the nearest thousand. Uncertainty intervals for DALY rates and PAFs are available in the 
appendix (pp 104–14). HCV=hepatitis C virus. DALY=disability-adjusted life-year.
Table 3: Burden of disease of HCV attributable to injecting drug use by region, 1990 and 2013 
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Men Women All
Mean (95% UI) Age-
standardised 
rate per 
100 000
Population 
attributable 
fraction (%)
Mean (95% UI) Age-
standardised 
rate per 
100 000
Population 
attributable 
fraction
Mean (95% UI) Age-
standardised 
rate per 
100 000
Population 
attributable 
fraction (%)
HIV burden
HIV/AIDS mycobacterial
DALYs 145 000
(109 000–216 000)
4·0
(3·0–5·9)
5·7%
(4·9–7·3)
38 000
(29 000–50 000)
1·0
(0·8–1·4)
2·1%
(1·8–2·6)
183 000
(140 000–263 000)
2·5
(1·9–3·6)
4·2%
(3·7–5·3)
YLDs 11 000 (6000–20 000) 0·3
(0·2–0·6)
7·0%
(5·2–9·0)
2000 (1000–4000) 0·1
(0·0–0·1)
2·2%
(1·8–2·7)
14 000 (7000–23 000) 0·2
(0·1–0·3)
5·1%
(3·9–6·6)
YLLs 134 000
(99 000–203 000)
3·6
(2·7–5·5)
5·6%
(4·7–7·3)
35 000
(27 000–47 000)
1·0
(0·7–1·3)
2·1%
(1·8–2·6)
169 000
(128 000–250 000)
2·3
(1·8–3·4)
4·2%
(3·6–5·3)
Deaths 3000 (2000–5000) 0·1
(0·1–0·1)
6·3%
(5·3–8·1)
1000 (1000–1000) 0·0
(0·0–0·0)
2·4%
(2·0–2·9)
4000 (3000–6000) 0·1
(0·0–0·1)
4·7%
(4·1–6·0)
HIV/AIDS other
DALYs 1 948 000
(1 587 000–2 776 000)
53·2
(43·3–76·0)
5·7%
(4·9–7·4)
687 000
(574 000–872 000)
18·9
(15·8–24·0)
2·2%
(1·9–2·6)
2 635 000
(2 235 000–3 552 000)
36·1
(30·6–48·6)
4·0%
(3·5–5·0)
YLDs 125 000 (2000–192 000) 3·5
(2·3–5·3)
6·4%
(5·3–8·2)
47 000 (32 000–8000) 1·3
(0·9–1·9)
2·6%
(2·2–3·0)
172 000 (116 000–261 000) 2·4
(1·6–3·6)
4·5%
(3·9–5·7)
YLLs 1 823 000
(1 488 000–2 606 000)
49·7
(40·5–71·0)
5·7%
(4·8–7·4)
639 000
(533 000–813 000)
17·6
(14·7–22·3)
2·2%
(1·9–2·6)
2 462 000
(2 086 000–3 314 000)
33·7
(28·5–45·3)
4·0%
(3·5–5·0)
Deaths 43 000 (35 000–61 000) 1·2
(1·0–1·7)
6·4%
(5·5–8·2)
14 000 (12 000–18 000) 0·4
(0·3–0·5)
2·4%
(2·1–2·9)
57 000 (48 000–76 000) 0·8
(0·7–1·1)
4·5%
(4·0–5·7)
Total HIV
DALYs 2 093 000
(1 709 000–2 970 000)
57·2
(46·6–81·3)
5·7%
(4·9–7·3)
724 000
(605 000–919 000)
19·9
(16·7–25·3)
2·2%
(1·9–2·6)
2 818 000
(2 385 000–3 811 000)
38·6
(32·7–52·2)
4·0%
(3·5–5·0)
YLDs 137 000 (91 000–209 000) 3·8
(2·5–5·8)
6·5%
(4·9–7·3)
50 000 (34 000–71 000) 1·4
(0·9–2·0)
2·6%
(2·1–3·0)
186 000 (127 000–280 000) 2·6
(1·8–3·9)
4·6%
(3·9–5·7)
YLLs 1 957 000
(1 600 000–2 779 000)
53·4
(43·6–75·7)
5·7%
(4·8–7·3)
675 000
(563 000–861 000)
18·6
(15·5–23·6)
2·2%
(1·9–2·6)
2 631 000
(2 224 000–3 554 000)
36·0
(30·5–48·6)
4·0%
(3·5–5·0)
Deaths 46 000 (38 000–66 000) 1·3
(1·0–1·8)
6·4%
(5·4–8·2)
15 000 (13 000–19 000) 0·4
(0·3–0·5)
2·4%
(2·1–2·9)
61 000 (52 000–82 000) 0·8
(0·72–1·1)
4·5%
(4·0–5·7)
HBV burden
Acute HBV infection
DALYs 13 000
(6000–22 000)
0·4
(0·2–0·6)
0·8%
(0·4–1·3)
2000
(1000–4000)
0·1
(0·0–0·1)
0·3%
(0·1–0·4)
16 000
(7000–25 000)
0·2
(0·1–0·4)
0·6%
(0·3–1·0)
YLDs 1000 (<500–2000) 0·0
(0·0–0·1)
1·2%
(0·5–1·8)
<500 (<500–1000) 0·0
(0·0–0·0)
0·5%
(0·2–0·7)
2000 (1000–3000) 0·0
(0·0–0·0)
0·9%
(0·4–1·4)
YLLs 12 000
(5000–20 000)
0·4
(0·2–0·6)
0·8%
(0·4–1·3)
2000
(1000–3000)
0·1
(0·0–0·1)
0·2%
(0·1–0·4)
14 000
(6000–23 000)
0·2
(0·1–0·3)
0·6%
(0·3–0·9)
Deaths <500 (<500–1000) 0·0
(0·0–0·0)
0·9%
(0·4–1·5)
<500 (<500 to 500) 0·0
(0·0–0·0)
0·3%
(0·1–0·5)
<500 (<500–1000) 0·0
(0·0–0·0)
0·7%
(0·3–1·1)
Liver cancer
DALYs 92 000
(44 000–146 000)
2·7
(1·3–4·3)
1·4%
(0·6–2·1)
9000
(4000–14 000)
0·3
(0·1–0·4)
0·5%
(0·2–0·8)
101 000
(48 000–160 000)
1·5
(0·7–2·3)
1·2%
(0·5–1·8)
YLDs 1000 (<500–1000) 0·0
(0·0–0·0)
1·4%
(0·6–2·2)
<500 (<500 to 500) 0·0
(0·0–0·0)
0·5%
(0·2–0·8)
1000 (<500–1000) 0
(0·0–0·0)
1·2%
(0·5–1·9)
YLLs 91 000
(43 000–145 000)
2·7
(1·3–4·3)
1·4%
(0·6–2·1)
9000
(4000–14 000)
0·3
(0·1–0·4)
0·5%
(0·2–0·8)
100 000
(47 000–159 000)
1·5
(0·7–2·3)
1·2%
(0·5–1·8)
Deaths 3000 (1000–5000) 0·1
(0·0–0·2)
1·3%
(6·0–2·0)
<500 (<500–1000) 0·0
(0·0–0·0)
0·5%
(0·2–0·7)
3000 (2000–5000) 0·1
(0·0–0·1)
1·1%
(0·5–1·7)
Liver cirrhosis
DALYs 81 000
(36 000–128 000)
2·3
(1·1–3·7)
1·3%
(0·6–2·0)
18 000
(8000–29 000)
0·5
(0·2–0·8)
0·6%
(0·3–1·0)
99 000
(44 000–157 000)
1·4
(0·6–2·2)
1·0%
(0·5–1·6)
YLDs 1000 (<500–2000) 0·0
(0·0–0·1)
1·3%
(0·6–2·1)
<500 (<500–1000) 0·0
(0·0–0·0)
0·7%
(0·3–1·1)
2000 (1000–3000) 0·0
(0·0–0·0)
1·1%
(0·5–1·7)
(Table 4 continues on next page)
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Men Women All
Mean (95% UI) Age-
standardised 
rate per 
100 000
Population 
attributable 
fraction (%)
Mean (95% UI) Age-
standardised 
rate per 
100 000
Population 
attributable 
fraction (%)
Mean (95% UI) Age-
standardised 
rate per 
100 000
Population 
attributable 
fraction (%)
(Continued from previous page)
YLLs 80 000
(36 000–126 000)
2·3
(1·0–3·7)
1·3%
(0·6–2·0)
18 000
(8000–28 000)
0·5
(0·2–0·8)
0·6%
(0·3–1·0)
97 000
(44 000–155 000)
1·4
(0·6–2·2)
1·0%
(0·5–1·6)
Deaths 2000 (1000–4000) 0·1
(0·0–0·1)
1·2%
(0·5–1·9)
1000 (<500–1000) 0·0
(0·0–0·0)
0·5%
(0·2–0·9)
3000 (1000–5000) 0
(0·0–0·1)
0·9%
(0·4–1·5)
Total HBV
DALYs 187 000
(87 000–292 000)
5·4
(2·5–8·6)
1·3%
(0·6–1·9)
29 000
(13 000–46 000)
0·8
(0·4–1·3)
0·5%
(0·2–0·8)
216 000
(101 000–338 000)
3·1
(1·5–4·9)
1·0%
(0·5–1·6)
YLDs 3000 (1000–5000) 0·1
(0·0–0·2)
1·3%
(0·6–2·0)
1000 (<500–1000) 0·0
(0·0–0·0)
0·5%
(0·2–0·9)
4000 (2000–7000) 0·1
(0·0–0·1)
1·0%
(0·5–1·6)
YLLs 183 000
(85 000–288 000)
5·4
(2·5–8·5)
1·3%
(0·6–1·9)
28 000
(13 000–45 000)
0·8
(0·4–1·3)
0·5%
(0·2–0·8)
212 000
(99 000–332 000)
3·1
(1·4–4·8)
1·0%
(0·5–1·6)
Deaths 6000 (3000–9000) 0·2
(0·1–0·3)
1·2%
(0·5–1·9)
1000 (<500–2000) 0·0
(0·0–0·1)
0·5%
(0·2–0·8)
7000 (3000–11 000) 0·1
(0·0–0·2)
1·0%
(0·4–1·6)
HCV burden
Acute HCV infection
DALYs 25 000 (7000–56 000) 0·7
(0·2–1·5)
28·8%
(22·6–35·3)
6000 (2000–13 000) 0·2
(0·1–0·4)
13·1%
(10–16·7)
32 000 (10 000–68 000) 0·4
(0·1–0·9)
23·0%
(18·6–27·6)
YLDs 3000 (2000–4000) 0·1
(0·0–0·1)
29·8%
(24·9–34·2)
1000 (1000–2000) 0·0
(0·0–0·1)
15·4%
(12·1–18·5)
4000 (2000–6000) 0·1
(0·0–0·1)
23·1%
(19–26·8)
YLLs 22 000 (5000–53 000) 0·6
(0·1–1·5)
28·8%
(22–36·1)
5000 (1000–12 000) 0·1
(0·0–0·3)
12·6%
(9·6–16·5)
28 000 (6000–64 000) 0·4
(0·1–0·9)
23·0%
(18·4–28·2)
Deaths 1000 (<500–1000) 0·0
(0·0–0·0)
28·5%
(22–35·9)
<500 (<500 to 500) 0·0
(0·0–0·0)
10·7%
(8·0–13·8)
1000 (<500–2000) 0·0
(0·0–0·0)
21·4%
(17·1–25·9)
Liver cancer
DALYs 2 771 000
(2 154 000–3 355 000)
82·1
(63·7–99·7)
47·7%
(39·8–54·4)
418 000
(323 000–523 000)
12·1
(9·3–15·1)
19·3%
(15·0–23·4)
3 189 000
(2 489 000–3 835 000)
46·4
(36·2–55·9)
40·0%
(32·9–46)
YLDs 22 000 (14 000–32 000) 0·7
(0·4–1·0)
43·3%
(35·4–50·4)
4000 (2000–6000) 0·1
(0·1–0·2)
16·2%
(12·1–20·2)
26 000 (17 000–37 000) 0·4
(0·3–0·6)
34·8%
(27·8–40·9)
YLLs 2 749 000
(2 132 000–3 331 000)
81·4
(63·1–99·0)
47·8%
(39·8–54·5)
414 000
(320 000–518 000)
12·0
(9·2–15)
19·3%
(15–23·5)
3 163 000
(2 467 000–3 806 000)
46·0
(35·9–55·4)
40·0%
(33–46·1)
Deaths 93 000 (72 000–113 000) 2·9
(2·2–3·6)
39·6%
(32·2–46·3)
16 000 (12 000–21 000) 0·5
(0·4–0·6)
14·9%
(11·1–18·6)
109 000 (84 000–132 000) 1·7
1·7 (1·3–2·0)
31·7%
(25·1–37·5)
Liver cirrhosis
DALYs 2 902 000
(2 490 000–3 364 000)
83·2
(71–96·6)
47·3%
(40·3–53·4)
924 000
(744 000–1 114 000)
26·0
(20·9–31·5)
24·4%
(19·7–29·2)
3 826 000
(3 264 000–4 441 000)
54·3
(46·1–63·2)
38·5%
(32·7–43·5)
YLDs 43 000 (29 000–61 000) 1·2
(0·8–1·7)
49·9%
(43·1–56)
16 000 (11 000–23 000) 0·5
(0·3–0·7)
49·9%
(43·1–56)
59 000 (40 000–83 000) 0·8
(0·6–1·2)
40·8%
(35–45·9)
YLLs 2 859 000
(2 450 000–3 317 000)
81·9
(69·9–95·4)
47·2%
(40·2–53·4)
908 000
(732 000–1 095 000)
25·6
(20·6–30·9)
24·4%
(19·6–29·2)
3 767 000
(3 209 000–4 372 000)
53·5
(45·3–62·3)
38·5%
(32·7–43·4)
Deaths 86 000 (72 000–100 000) 2·6
(2·2–3·1)
41·6%
(34·8–47·7)
29 000 (22 000–35 000) 0·8
(0·6–1·0)
19·0%
(14·7–23·4)
114 000 (95 000–135 000) 54·3
(46·1–63·2)
32·0%
(26·7–36·9)
Total HCV
DALYs 5 698 000
(4 754 000–6 588 000)
165·9
(138·1–192·8)
47·3%
(40–53·3)
1 348 000
(1 081 000–1 609 000)
38·3
(30·6–45·8)
22·5%
(18·1–26·7)
7 046 000
(5 882 000–8 153 000)
101·1
(83·9–117·3)
39·1%
(31·4–42·7)
YLDs 68 000 (46 000–93 000) 2·0
(1·4–2·7)
46·3%
(39·6–52·2)
21 000 (14 000–30 000) 0·6
(0·4–0·8)
23·5%
(19·1–27·9)
89 000 (61 000–123 000) 1·3
(0·9–1·8)
37·6%
(30·4–41·2)
YLLs 5 630 000
(4 697 000–6 505 000)
163·9
(136·4–190·5)
47·4%
(40·0–53·3)
1 327 000
(1 064 000–1 586 000)
37·7
(30·2–45·1)
22·4%
(18·1–26·7)
6 957 000
(5 806 000–8 048 000)
99·8
(82·7–115·8)
39·1%
(31·4–42·7)
Deaths 179 000
(146 000–211 000)
5·5
(4·5–6·6)
40·5%
(33·6–46·7)
45 000
(35 000–56 000)
1·3
(1·0–1·6)
17·2%
(13·3–21·3)
224 000
(182 000–264 000)
3·3
(2·7–4·0)
31·8%
(24·3–35·2)
Burden was measured as DALYs, YLDs, YLLs, and deaths. HBV=hepatitis B virus. HCV=hepatitis C virus. DALY=disability-adjusted life-year. YLD=years of life lived with disability. YLL=years of life lost. 
PAF=population attributable fraction.
Table 4: Burden of disease attributable to injecting drug use by outcome and sex, 2013 
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group. Where we report rates of DALYs, YLLs, YLDs, or 
deaths by country or region, we used the revised 
GBD 2013 world population standard for the age-
standardisation of these rates. Details of the age-standard 
and its development have been reported previously.1
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Globally, the number of DALYs attributable to IDU for 
HIV (table 1), HBV (table 2), and HCV (table 3) nearly 
quadrupled between 1990 and 2013, from 2 661 000 to 
10 080 000 (appendix pp 104–14 for UIs around estimates 
of age-standardised DALY rates and population 
attributable fractions in these tables). The contribution 
Figure 1: Distribution of absolute DALYs attributable to injecting drug use, 2013
DALYs attributable to injecting drug are for HIV (A), hepatitis C virus (B), hepatitis B virus (C), and HIV, hepatitis C virus, and hepatitis B virus combined (D). DALY=disability-adjusted life-year.
Andean Latin America
0%
Andean Latin America
1%
Australasia
0%
Australasia
0%
Caribbean
0%
Caribbean
0%
Central Asia
2%
Central Asia
1%
East 
Asia
6%
East Asia
34%
Central Latin America
0%
Central Latin America
3%
Tropical Latin America
1%
Tropical Latin America
4%
Southern Latin America
0%
Southern Latin America
2%
Central Europe
0%
Central Europe
2%
Eastern 
Europe
20%
Eastern Europe
9%
Western Europe
1%
Western Europe
10%
Eastern sub-Saharan
Africa
9%
Eastern sub-Saharan
Africa
3%
Southern sub-Saharan 
Africa
8%
Southern sub-Saharan Africa
0%
Western sub-
Saharan Africa
28%
Western sub-Saharan Africa
1%
High-income North America
2% High-income 
North America
11%North Africa and Middle East
3%
North Africa and 
Middle East
2%
Oceania
0%
Oceania
0%
Oceania
0%
Oceania
0%
South Asia
1%
South Asia
3%
Southeast 
Asia
17%
Southeast Asia
7%
High-income Asia Pacific
0%
High-income 
Asia Pacific
5%
Central sub-Saharan
Africa
1%
Central sub-Saharan Africa
1%
Andean Latin America
1%
Australasia
0%
Caribbean
0%
Central Asia
1%
East Asia
27%
Central Latin America
2%
Tropical Latin America
3%
Southern Latin America
1%
Central Europe
2%
Eastern Europe
12%
Western Europe
7%
Eastern sub-Saharan
Africa
4%
Southern sub-Saharan Africa
2%
Western sub-Saharan Africa
9%
High-income North America
9%
High-income 
North America
9%
North Africa and 
Middle East
2%
South Asia
3%
Southeast Asia
10%
High-income 
Asia Pacific
4%
Central sub-
Saharan Africa
1%
Andean Latin America
1%
Australasia
0%
Caribbean
0%
Central Asia
3%
East Asia
44%
Central Latin America
1%
Tropical Latin America
1%
Southern Latin America
1%
Central Europe
3%
Eastern Europe
7%
Western Europe
6%
Eastern sub-
Saharan
Africa
1%
Southern sub-Saharan Africa
0%
Western sub-Saharan Africa
3%
North Africa and 
Middle East
3%
South Asia
4%
Southeast Asia
7%
High-income 
Asia Pacific
5%
Central sub-Saharan Africa
0%
A B
C D
Articles
www.thelancet.com/infection   Vol 16   December 2016 1393
that injecting made to these causes of disease burden 
over time varied substantially across regions in 
(tables 1–3; appendix pp 104–14 for UIs).
Viral hepatitis arising from IDU was a far bigger 
contributor to disease burden than was HIV in both 1990 
and 2013. HCV was the largest contributor to the burden 
of IDU by a substantial margin (table 3), accounting for 
7·05 million DALYs (95% UI 5·88 million to 8·15 million) 
in 2013. Almost all HCV-related burden attributed to 
IDU was from liver cirrhosis (3·83 million DALYs 
globally, 95% UI 3·26 million to 4·44 million) and liver 
cancer (3·19 million DALYs, 95% UI 2·49 million to 
3·84 million; table 4) By comparison, there were 
2·82 million DALYs (95% UI 2·39 million to 3·81 million) 
for all HIV outcomes attributable to IDU and 
0·22 million DALYs (95% UI 0·10 million to 0·34 million) 
for all HBV outcomes attributable to IDU. Most of the 
disease burden attributable to IDU was due to YLLs 
rather than YLDs. In 2013, IDU was estimated to cause 
4·0% (2·82 million, 95% UI 2·4 million to 3·8 million) 
of total DALYs due to HIV, 1·1% (216 000, 101 000–338 000) 
of total DALYs due to HBV, and 39·1% (7·05 million; 
5·88 million to 8·15 million) of total DALYs due to HCV.
Figure 1 shows the distribution of DALYs due to HBV, 
HCV, and HIV attributable to IDU, by GBD region. The 
regions diﬀ ered noticeably in their contributions to the 
global burden of each blood-borne viral infection. For 
example, we estimated that regions in Asia jointly 
accounted for nearly two-thirds of global HBV burden 
(62%) and half of the global HCV (50%) burden 
attributable to IDU. The contribution to global burden 
was particularly high in east Asia, which had 44% of 
total HBV burden and 34% of total HCV burden. By 
contrast, these regions accounted for only 26% of global 
IDU-attributable HIV burden. Regions in 
sub-Saharan Africa accounted for 46% of 
IDU-attributable HIV burden, but had much smaller 
proportions of IDU-attributable HBV and HCV (both 
5%). High-income North America was estimated to 
account for roughly a tenth of global IDU-attributable 
HCV (11%) and HBV burden (9%), but only 2% of HIV 
burden attributable to IDU. In terms of IDU-attributable 
burden, eastern Europe accounted for an estimated 20% 
of HIV burden, 9% of HCV burden, and 7% of HBV 
burden (table 3, ﬁ gure 1; appendix p 105).
Table 4 also provides global estimates of burden due 
to speciﬁ c consequences of HIV, HBV, and HCV 
infection in 2013 by sex. The IDU-attributable burden 
of infection was higher in men than in women for 
consequences of all three infections (table 4). At the 
global level, IDU in men was the cause of 5·7% of HIV 
DALYs, 47·3% of HCV DALYs, and 1·3% of HBV 
VCT
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Figure 2: Proportion of total burden of HIV attributable to injecting drug use by country, 2013 
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micronesia.
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DALYs (table 2). In women, IDU was the cause of 2·2% 
of HIV DALYs, 22·5% of HCV DALYs, and 0·8% of 
HBV DALYs.
In 2013, the highest age-standardised DALY rates for 
HIV attributable to IDU were in eastern Europe and 
sub-Saharan Africa. The greatest population attributable 
fractions for HIV were in central Asia (64%), 
eastern Europe (44%), and east Asia (26%; table 1).
We assessed population attributable fraction of IDU as 
a risk factor for HIV (ﬁ gure 2), HCV (ﬁ gure 3), and HBV 
(ﬁ gure 4) by country. Country-level DALYs and DALY 
rates and population attributable fractions for all 
IDU-attributable burden and burden for HIV, HBV, and 
HCV are reported in detail in the appendix (pp 107–14). 
The contribution of IDU to burden varied by country 
(ﬁ gures 2, 3, and 4). For HIV, the countries in which IDU 
accounted for the greatest proportion of HIV burden 
were in Asia and eastern Europe (ﬁ gure 2). Countries in 
which we estimated that at least 60% of HIV burden was 
attributable to IDU included Iran, Azerbaijan, 
Kyrgyzstan, Uzbekistan, Malaysia, Kazakhstan, 
Turkmenistan, and Georgia. Countries in which the 
estimated contribution of IDU to HCV burden was 
highest were Canada, the USA, Denmark, and New 
Zealand (ﬁ gure 3). IDU made a small contribution to 
HBV burden in all countries (ﬁ gure 4).
Discussion
Globally, in 2013, more than 10 million DALYs were 
estimated to be attributable to previous exposure to HIV, 
HBV, and HCV via IDU. This represents a four-times 
increase in DALYs since 1990. Most of this burden was 
due to YLLs. The majority of attributable burden was due 
to HCV infection and its consequences. HCV burden 
attributable to IDU was more than 2·5 times the burden 
of HIV attributable to injecting.
The contribution that IDU was estimated to have made 
to the burden of disease varied substantially between 
diﬀ erent geographic regions. Contributions of IDU to 
HIV burden were highest in low-to-middle-income 
countries, whereas the contributions of IDU to HCV 
burden were highest in high-income countries.
Eﬀ ective and cost-eﬀ ective interventions are available to 
reduce the burden of all three blood-borne viral infections. 
Eﬃ  cacious treatments for HIV have been available for 
20 years, but coverage among people who inject drugs is 
negligible.3,41 The recent development of much more 
eﬀ ective and less toxic drugs to treat HCV infection should 
substantially improve what have previously been extremely 
low rates of treatment for HCV infection among people 
who inject drugs.42,43 Cure rates of 90% or more can be 
achieved by 8–24 weeks of oral tablets for all HCV 
genotypes, including in people with cirrhosis or who have 
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co-infection with HIV.44 These agents represent a 
therapeutic revolution. There have been limited eﬀ orts to 
increase access in low resource settings, and access to 
generic versions of several of these antivirals typically 
remains very low in many countries. The situation is 
similar for chronic HBV infection, for which highly potent 
and well tolerated oral agents45 that suppress viral 
replication have been available for more than a decade.46 
Access to these drugs remains low in many countries, 
despite the widespread availability of one antiviral 
(tenofovir) in combination antiretroviral regimens for 
HIV treatment. Further eﬀ orts are needed to ensure 
access to these essential medicines in low-resource 
settings, especially in countries in which people who 
inject drugs have less access to health-care systems.
Barriers to treatment include low diagnosis rates, un-
warranted restrictions on treatment access, and medicine 
costs.47 Case-ﬁ nding, referral, and active management are 
crucial for the prevention of morbidity in people with a 
history of IDU. In the USA, there have been recom-
mendations for birth cohort screening, which is 
controversial, and in the USA is only cost-eﬀ ective when 
levels of infection in the general community are higher 
than 1–2%.48–50 Few trials have investigated case-ﬁ nding 
for people with a history of IDU in low-income and 
middle-income countries.
Good evidence also exists for the eﬀ ectiveness of 
prevention of HIV, HBV, and HCV. Much of the burden 
attributable to HIV could be averted by scaling up of 
needle and syringe programmes and provision of opioid 
substitution treatment and antiretroviral therapy.30,40,51,52 
Increasing HCV burden could also be reduced by 
expansion of needle and syringe programmes and opioid 
substitution therapy.30,53 Findings from systematic 
reviews have shown that injecting risk and HIV incidence 
are reduced by the provision of opioid substitution 
therapy to opioid-dependent injecting drug users.54,55 
However, in many countries, coverage of these inter-
ventions is very low among people who inject drugs.3 The 
curative, short-course nature of new HCV treatments 
means that treatment scale-up might produce secondary 
prevention beneﬁ ts,43 although this has yet to be tested 
empirically.56 Additionally, there is increasing recognition 
of the potential of HIV and HCV treatment to prevent 
infection,40,43,53 reinforcing the importance of scale-up of 
these treatments to people with HIV and HCV infection 
to reduce future transmission.
Infant vaccination and antenatal screening programmes 
are essential to the prevention of chronic of HBV infection 
in most countries; if implemented successfully, these 
approaches would reduce incidence HBV infection in 
people who subsequently inject drugs. Selective vaccination 
Figure 4: Proportion of total burden of hepatitis B virus attributable to injecting drug use by country, 2013
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micronesia.
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programmes against HBV among injecting drug users in 
countries with low endemic rates of HBV have often had 
low uptake because of the diﬃ  culty of reaching the most 
at-risk individuals.57 Correctional facilities provide one 
opportunity to vaccinate, treat, and reduce the transmission 
of viral hepatitis in countries in which there are high levels 
of IDU, HBV, and HCV,39,58 because many prisoners cycle 
in and out of the community. However, given the small 
contribution of IDU to HBV burden, the overall eﬀ ect of 
HBV vaccination in prisoners who inject drugs is likely to 
be small at the population level.
The overall GBD project has limitations that have 
been discussed in detail in previous studies.2,8,9,13,59,60 
These limitations relate to gaps in data, variable quality 
of the data that do exist, controversies over the methods 
used to generate the disability weights that are applied 
to estimate non-fatal disease burden, and in the 
modelling that is used to generate internally consistent 
disease-speciﬁ c models.
A range of limitations speciﬁ c to this study also exist. 
The limited amount of data on the population-level 
exposure (IDU) and the risk of HIV, HBV, and HCV 
infection in people who inject drugs generates un-
certainty in our estimates. This uncertainty is especially 
marked in some countries, such as those in Africa, where 
few data exist on IDU and the incidence and prevalence 
of infection. There is therefore substantial variation in 
the uncertainty around the estimates we have made 
across countries. In the case of countries for which there 
were no country-speciﬁ c data inputs into the models, the 
levels imputed might vary from actual levels. It is unclear 
whether there would be systematic bias either upwards 
or downwards in these estimates. Given that the GBD 
project is ongoing, however, to the extent that new data 
are collected and may be included to inform models, the 
estimates made in future iterations will have less 
uncertainty.
We extrapolated exposure to IDU before 1990 for the 
purposes of generating estimates of historical exposure 
to HBV and HCV via injection. Substantial uncertainty 
exists in this modelling because there are few data on 
trends in the prevalence of IDU and exposure to 
blood-borne viruses before 1990.
We attributed all excess infections among people who 
inject drugs to their IDU. For HIV, the proportion of 
infections due to sexual risk and injecting risk can vary 
among countries.61 Nonetheless, in our analyses, most 
HIV infections were attributed to IDU, and we were not 
able to take account of the role of exposure via multiple 
transmission routes. Additionally, we assumed a uniform 
average risk of infection with HCV and HBV during 
active injecting periods, whereas some people who inject 
drugs are at greater risk of exposure than are others.
IDU is a major contributor to the global burden of 
disease due to infection with blood-borne viruses. 
Scale-up of eﬀ ective interventions is needed to prevent 
and treat these important causes of health burden 
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among people who inject drugs. With HBV and HCV 
now estimated to cause more deaths globally than HIV 
infection,1,9 the political and health-care mobilisation 
that reduced the number of deaths from HIV infection 
over the past decade must be implemented for viral 
hepatitis. WHO’s draft Global Health Sector Strategy 
on viral hepatitis, 2016–2021 provides a good blueprint 
for the elimination of viral hepatitis as a major public 
health concern by 2030.62 This strategy sets targets that 
include 50% of people who inject drugs being covered 
by harm reduction services by 2020, and 90% of people 
living with viral hepatitis being diagnosed and 90% of 
eligible people treated by 2030. Additionally, the 2016 
Political Declaration on HIV and AIDS reaﬃ  rmed 
countries’ intention to combat HIV and AIDS by 
scaling up universal access to prevention, treatment, 
and care.63 Both this declaration and the Global 
Fund acknowledge that treatment of viral hepatitis 
co-infections is important. Commitment by all 
countries, and strong engagement across government 
sectors and with all partners to the response, is crucial 
to meeting these objectives, which will save millions of 
lives in coming years.
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